The psychiatric side-effects of rimonabant

[Commentary] TRIAL COMES TOO LATE AS PSYCHIATRIC SIDE EFFECTS END HOPE FOR RIMONABANT

(2009)   ADDICTION

A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain

(2009) Nancy A. Rigotti et al.   ADDICTION

The endocannabinoid system: emotion, learning and addiction

(2008) Fabrício A. Moreira et al.   ADDICTION BIOLOGY

Effect of Rimonabant on the High-Triglyceride/ Low–HDL-Cholesterol Dyslipidemia, Intraabdominal Adiposity, and Liver Fat

(2008) Jean-Pierre Després et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

The Acyclic CB1R Inverse Agonist Taranabant Mediates Weight Loss by Increasing Energy Expenditure and Decreasing Caloric Intake

(2008) Carol Addy et al.   Cell Metabolism

SERENADE: The Study Evaluating Rimonabant Efficacy in Drug-Naive Diabetic Patients: Effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes

(2008) J. Rosenstock et al.   DIABETES CARE

Efficacy and Safety of Rimonabant for Improvement of Multiple Cardiometabolic Risk Factors in Overweight/Obese Patients: Pooled 1-year data from the Rimonabant in Obesity (RIO) program

(2008) L. Van Gaal et al.   DIABETES CARE

Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study †

(2008) Luc F. Van Gaal et al.   EUROPEAN HEART JOURNAL

The cannabinoid CB1receptor and the endocannabinoid anandamide: possible antidepressant targets

(2008) Francis Rodriguez Bambico et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Effect of Rimonabant on Progression of Atherosclerosis in Patients With Abdominal Obesity and Coronary Artery Disease

(2008) Steven E. Nissen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Taranabant, a Novel Selective Cannabinoid-1 Receptor Inverse Agonist, for the Treatment of Obesity: Results From a Double-Blind, Placebo-Controlled, Single Oral Dose Study in Health

(2008) Carol Addy et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Multiple-Dose Pharmacokinetics, Pharmacodynamics, and Safety of Taranabant, a Novel Selective Cannabinoid-1 Receptor Inverse Agonist, in Healthy Male Volunteers

(2008) Carol Addy et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action

(2008) Antonio Waldo Zuardi   REVISTA BRASILEIRA DE PSIQUIATRIA

Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists?

(2008) Vincenzo Di Marzo   Nature clinical practice. Cardiovascular medicine

Antiaversive Effects of Cannabinoids: Is the Periaqueductal Gray Involved?

(2008) F. A. Moreira et al.   NEURAL PLASTICITY

Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors

(2007) Fabricio A. Moreira et al.   NEUROPHARMACOLOGY